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The pathogenesis of HIV immunodeficiency is mainly dependent on the cytopatic effects
exerted by the virus against infected CD4+ T cells. However, CD4+ T cell loss cannot
be the only pathogenic factor since severe opportunistic infections may develop in HIV
infected patients with normal CD4+ T cell counts and since the recent START study
indicated that absolute CD4+ T cell counts are not predictive for AIDS and non-AIDS
events. Recently our group demonstrated that CD8+CD28-CD127lowCD39+ regulatory
T lymphocytes, previously found highly concentrated within tumor microenvironment,
circulate with elevated frequency in the peripheral blood of HIV infected patients. Here,
we show that these cells, that at least in part are HIV specific, express the PD1 immune
checkpoint. Based on these evidences and considerations, in this Perspective article
we speculate on the opportunity to treat HIV infected patients with anti-PD1 immune
checkpoint inhibitors as a way to counteract the T regulatory cell compartment and to
unleash virus-specific immune responses. In order to potentiate the immune responses
against HIV we also propose the potential utility to associate immune checkpoint
inhibition with HIV-specific therapeutic vaccination, reminiscent of what currently applied
in oncologic protocols. We suggest that such an innovative strategy could permit
drug-sparing regimens and, perhaps, lead to eradication of the infection in some patients.
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The pathogenesis of HIV immunodeficiency is dependent on the cytopatic eﬀects exerted by the
virus against infected CD4+ T cells and to subsequent CD4+ T cell loss (1, 2). Some aspects of the
disease remain unexplained as the case of HIV infected patients with normal CD4+ T cell counts
after anti-retroviral therapy (ART) initiation who develop severe opportunistic infections (3, 4), or
that of HIV infected patients with reduced CD4+T cell counts who do not show immunodeficiency
manifestations (5). Accordingly, the results of the recent START study indicated that absolute
CD4+ T cell counts are not predictive for AIDS and non-AIDS events since these events may
occur in ART treated patients with absolute CD4 counts >500 cells/µl (6). Searching for other
pathogenic mechanisms, we focused our attention on regulatory T lymphocytes (Treg). The role
of these cells in HIV immunodeficiency pathogenesis is still unclear since studies on alterations
of CD4+ Treg in HIV infected patients led to controversial results (7–17). Hence, we took into
consideration a diﬀerent subset of Treg constituted by CD8+ Treg (18). CD8+ Treg, in particular
those expressing the CD8+CD28-CD127lowCD39+ phenotype, are regulatory T lymphocytes
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found highly concentrated within tumor microenvironment,
where they can exert remarkable immunosuppressive activity due
to their capacity to target T cell proliferation and cytotoxicity
(19–21). We investigated on the presence of these cells in
the circulation of HIV-infected patients, and on possible
correlations between their frequency and markers of disease
activity. The results of this study demonstrated that HIV-
infected patients have elevated circulating levels of functional
CD8+CD28-CD127lowCD39+ Treg, the majority of which is
antigen-specific for HIV proteins. This observation is remarkable
since these cells are virtually absent from the circulation of
FIGURE 1 | CD8+CD28−CD127loCD39+PD1+ Treg frequency in the peripheral blood of naïve HIV-infected patients. (A) The gating strategy for the analysis of
CD8+CD28−CD127loCD39+PD1+ Treg frequency in the circulation of two representative naïve HIV-infected patients is shown. (B) Comparison between the mean
frequency of CD8+CD28−CD127loCD39+ Treg as well as that of CD8+CD28−CD127loCD39+PD1+ Treg in the circulation of 22 naïve HIV-infected patients and
those of 22 healthy controls. Detailed information on patient population and methods is provided in the Supplementary File—Patients and Methods.
healthy subjects (19, 21). In HIV patients, their frequency
post-ART correlates with HIV-RNA, CD4+ T cell count,
and immune activation markers, suggesting their pathogenic
involvement in AIDS or non-AIDS related complications.
Moreover, their increase after initiation of ART heralds a lack of
virological or clinical response (i.e., appearance of co-morbidity):
hence their monitoring is clinically relevant (22).
Further studies from our group show that
CD8+CD28-CD127lowCD39+ Treg stably and consistently
express PD1 (Figure 1 and Supplemental Material). PD1
is a member of immune checkpoints (23–26). These are
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molecules expressed by immune cells in order to control the
immune responses. In particular, PD1 is mainly expressed by
T lymphocytes at advanced stage of maturation, i.e., eﬀector
memory and terminally-diﬀerentiated eﬀector memory cells.
Hence, it is involved in the control of the eﬀector phase of
the immune response. Indeed, PD1+ T cells are present
within tumor infiltrating lymphocytes, suggesting that PD1
expression contributes to tumor immune evasion (24, 27).
In HIV-infected patients CD4+PD1+ T cells constitute the
major HIV cell reservoir (28, 29). Interestingly, PD1+ T cell
frequency is elevated in HIV-infected patients and reduces
after beginning of the treatment, a behavior reminiscent of
what occurs to circulating CD8+CD28-CD127loCD39+ Treg
frequency (30, 31). In HIV-infected patients, the presence of
increased frequency of PD1+ T cells, including abnormally
expanded CD8+CD28-CD127loCD39+PD1+ Treg, could
be involved in generating immunodeficiency and hampering
anti-virus immune responses. Hence, the fact that expansion of
CD8+ Treg and of PD1+ T lymphocytes co-exist in both tumors
and HIV infection envisages a pathogenic crossing between
the two pathologic conditions. This suggests that targeting
PD1+ T cells through a specific checkpoint inhibitor could
be a useful therapeutic strategy for HIV infection borrowed
from anti-cancer protocols, based that recent trials support the
safety of this approach (32, 33). The potential eﬃcacy of this
strategy is further supported by previous studies in which a
PD1 inhibitor was administered to non-human primates. In
these studies, anti-PD1 treatment of uninfected animals co-
immunized with a SIV-gag adenovirus vector vaccine enhanced
the frequency of gag-specific T cells (34), while treatment of
SIV infected macaques increased SIV-specific immune response,
decreased viral load and prolonged survival (35). Accordingly,
administration of anti-PD-L1 monoclonal antibodies to ART-
treated SIV infected macaques allowed the maintenance of a
lower viral load after ART suspension than in non-administered
animals (36).
However, in the majority of cancer patients the activity
of the sole checkpoint inhibitor is not suﬃcient to provide
a robust therapeutic eﬀect. Hence, association of checkpoint
inhibitors with therapeutic vaccination is currently proposed
as optimal way for inducing/reinforcing anti-tumor immune
responses in the absence of abnormal and detrimental regulatory
mechanisms (37, 38). Interestingly, the development of a vaccine
against HIV has been recently evoked as urgent medical need,
notwithstanding the eﬃcacy of ART. In fact, HIV pandemia is
so wide (more than 36 million infected people, about 1.8 million
people newly infected each year) that the costs for life-long
ART are huge for government health care systems. Hence,
therapeutic vaccination has been proposed as a preferential
therapeutic tool for corroborating ART activity possibly through
the eradication of HIV-1 latent reservoirs (39, 40). Indeed,
an optimal vaccine against HIV should elicit both virus-
specific cytotoxic CD8+ T cells and neutralizing antibodies
in order to kill virus-infected cells, that constitute the viral
reservoir, and to avoid spreading of infection by viral particles
released by already infected cells. Among HIV antigens, gag has
been considered a useful immunogen for vaccine preparation
since the presence of elevated titers of antibodies against gag,
but not against other HIV antigens, correlated with reduced
viremia in HIV infected patients (41). Disappointingly, all
vaccination trials so far performed in prophylactic or therapeutic
settings, including those using gag as immunogen, did not
achieve brilliant clinical results (42). Now, the finding of
an abnormal expansion of CD8+CD28-CD127loCD39+PD1+
Treg in these patients suggests that such defective activity of
HIV vaccines could have a bi-faceted origin, related to inner
deficiency of vaccine immunogenicity and/or to the generalized
immunosuppressive eﬀect exerted by CD8+ Treg. Accordingly,
a DNA vaccine based on a chimeric gene product fusing
PD1 and gag moieties induced high frequency of gag-specific
cytotoxic CD8+ T cells associated with high titers of virus-
specific antibodies, conferring remarkable protection against
mucosal challenge with vaccinia gag viruses in experimental
animals (43).
These considerations may constitute a robust rationale
for a combination therapy associating anti-PD1 checkpoint
inhibition and therapeutic vaccination in ART treated HIV-
infected patients. Our hypothesis is that early co-administration
of ART, checkpoint inhibition, and vaccination in recently
HIV-infected patients could allow to take advantage of
the synergic eﬀect of the three-faceted approach when the
HIV latent reservoir is not yet consolidated. We expect
that such an innovative strategy could lead to the onset
of HIV specific immune responses more eﬀective than
those spontaneously developed in the absence of Treg
inhibition, since unleashed by the regulatory control of
PD1+ Treg. Hopefully, this strategy could permit drug-sparing
regimens and, perhaps, lead to eradicate the infection in some
patients.
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